🟢 Nanobiotix is trading 5.5% up in pre-market after melanoma study showed 41.7% response rate

Nanobiotix is trading at $31.00, up 5.5% in pre-market on October 26 after reporting updated Phase 1 melanoma data on October 24.

• Among 24 heavily pre-treated, anti-PD-1-resistant patients, the study reported a 41.7% response rate, including four complete responses; median overall survival was 17.8 months.
• Presented at ESMO, the preliminary findings from a single-arm study were said by investigators to warrant evaluation in randomized trials.